Healthcare • NYSE
According to Zyberno, Electromed, Inc. (ELMD) is not a buy — GREAT BUSINESS (84/100) with a negative Margin of Safety of +8.4% and a Brina Gap of -16.3% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, Electromed, Inc. (ELMD) trades at $29.60 against an estimated intrinsic value per share of $32.32 — a +8.4% Margin of Safety based on Owner Earnings of $8.53M TTM, projected at 63.9% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -16.3% weakens the case: based on the company's ROIC (29.7%) and reinvestment rate (-7.6%), the business can fundamentally grow at -2.3% — but the current enterprise value implies the market expects 14.1%. This places ELMD in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 13.6% annually.
Over the trailing twelve months, ELMD generated $8.53M in Owner Earnings. Capital was deployed as follows: $1.00M returned via share buybacks, $477.00K invested in capital expenditures. Reinvestment rate: -7.6%. Owner Earnings have grown at 63.9% annually over the trailing five years using log-linear regression.